Teva Study Examines Treatment Selection in Schizophrenia
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
Teva
Advertisement
Teva Reports New TEV-749 Olanzapine LAI Clinical Data
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
Teva Reaches Investment Grade With S&P BBB- Upgrade
Tel Aviv, Israel, September 4, 2026 Teva Pharmaceutical Industries Ltd. has received an upgrade to BBB- from BB+ for...
Teva Advances U.S. Deal on Affordable Medicines and Supply
PARSIPPANY, N.J., and TEL AVIV, Israel, August 31, 2026 Teva Pharmaceuticals announced a shared commitment with the Trump Administration...
Teva Earns Investment-Grade Rating as Growth Strategy Advances
TEL AVIV, Israel, August 11, 2026 Teva Pharmaceutical Industries Ltd. announced that Moody’s Ratings has upgraded the company’s corporate...
Advertisements
Teva Expands Global Biosimilar Portfolio With Polpharma
TEL AVIV, Israel / ZUG, Switzerland | July 9, 2026 Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical...
Teva Launches AHZANTIVE Biosimilar to Eylea Across Europe
TEL AVIV, Israel, June 4, 2026 Teva Pharmaceutical Industries Ltd. has announced the European launch of AHZANTIVE® (aflibercept), an...
Teva Gains FDA Approval for PONLIMSI Biosimilar Drug
TEL AVIV, Israel & PARSIPPANY, N.J., USA, March 30, 2026 Teva Pharmaceutical Industries has received U.S. FDA approval for...
Teva Unveils Global Innovation Platform to Transform Pharma
Tel Aviv — November 19, 2025 — Teva Pharmaceutical Industries Ltd. has launched Teva Rise, a groundbreaking global open-innovation...
Advertisement
